AzTrials
AzTrials

AmputationTTeOPRANCT05249049

Osseointegrated Transtibial Prosthesis With Neural Interface

A study testing e-OPRA Implant System for Transtibial Amputees in people with Amputation, run by Massachusetts Institute of Technology at 2 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The e-OPRA Implant System, is a further development of the OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) Implant System. The e-OPRA Implant system is an implant system for direct skeletal anchorage of amputation prostheses. Read more about this study

Who is it for?
Ages 22 to 65 years
Conditions the study is for
Amputation
What is being tested?
e-OPRA Implant System for Transtibial Amputees
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
2 sitesUnited States
Study dates
3 Nov 2021to 15 Apr 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or Female age 22-65 at the time of surgery.
  • The patient must have an existing unilateral or bilateral transtibial amputation or a medical condition requiring performance of a unilateral or bilateral transtibial amputation with a minimum of 8 cm of residual tibia after amputation.
  • The subject must have undergone independent consultation with at least two lower extremity surgical specialists to ensure they have exhausted all limb salvage options prior to undergoing amputation, as well as a psychiatric evaluation to ensure appropriate capacity and volition.
  • The patient must have the ability to ambulate at variable cadence (an expected lower extremity prosthesis functional level of K3 or above).
  • The patient must have adequate bone stock to support the implanted device.
  • The patient must have adequate soft tissue bulk and muscle mass present in the operative limb to support appropriate wound healing and muscle end organ construction.
Show all 9Show fewer
  • In the opinion of the investigator, normal cognitive function and absence of any physical limitations, addictive diseases or underlying medical conditions that may preclude patient from being a good surgical and/or study candidate.
  • Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study including the prescribed rehabilitation program.
  • Written informed consent to participate in the study provided by the patient or legal representative.

Who cannot join

  • Women who are pregnant, lactating or planning a pregnancy during the first twelve (12) months of the post-surgical follow-up.
  • Subjects who have not been completely abstinent from tobacco use for at least 6 weeks preoperatively.
  • Subjects who weigh over 90 kg.
  • Subjects who have an active infection or dormant bacteria.
  • Subjects would have less than 2 mm of remaining cortex bone available around the implant, if implanted.
  • Subjects with advanced atrophic muscle and and/or compromised soft tissue coverage in the operative limb.
Show all 11Show fewer
  • Evidence of or a documented history of severe peripheral vascular disease, diabetes mellitus (type I or type II), skin diseases, Neuropathy or neuropathic disease and severe phantom pain, or osteoporosis, such that, in the opinion of the investigator, will not allow the subject to be a good study candidate.
  • Evidence of any active skin disease involving the proposed surgical limb.
  • History of systemically administered corticosteroids, immune-suppressive therapy or chemotherapy drugs within six (6) months of implant surgery.
  • Severe co-morbidity, atypical skeletal anatomy, or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectancy, vulnerable patient population, BMI >40, etc.).
  • The subject is currently involved in another clinical study where that participation may conflict or interfere with the treatment, follow-up or results of this clinical study.

Trial locations and contacts

2 sites in 1 country.

Hugh M Herr, PhD contact

617-314-3661

hherr@media.mit.edu

Matthew J Carty, MD contact

617-983-4555

mcarty@bwh.harvard.edu

United States2 sites, 2 recruiting
  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115

    Matthew J Carty, MD, 617-983-4555, mcarty@bwh.harvard.edu

    Recruiting
  • MIT Media Lab

    Cambridge, Massachusetts, 02139

    Hugh M Herr, PhD, 617-314-3661, hherr@media.mit.edu

    Recruiting

Other trials in United States

About this study

Official title: An Osseointegrated Transtibial Prosthesis Offering Long-Term Bi-Directional Efferent-Afferent Neural Transmission

The e-OPRA Implant System, is a further development of the OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) Implant System. The e-OPRA Implant system is an implant system for direct skeletal anchorage of amputation prostheses. The added feature in the e-OPRA Implant system, is a bidirectional interface into the human body that allows permanent and reliable communication using implanted electrodes. These electrodes will provide long-term stable bioelectric signals for an improved control of the prosthetic limb. The purpose of the study is to evaluate the feasibility of a transtibial amputee with the e-OPRA Implant System exhibiting full neural control over a neuro-mechanical prosthetic system.

A maximum of two subjects will be enrolled. Each subject will undergo a surgery where the e-OPRA Implant System will be implanted. The subjects will participate in follow-up sessions of which the last one occurs approximately 24 months after the surgery. This is a prospective, non-randomized, uncontrolled study.

Read the detailed description

Normalization of function for individuals with limb amputation is within reach, and will be achieved by smart implants capable of bi-directional communication between brain and machine via bone-anchored, interactive, powered prosthetic components. Rehabilitation of patients with expected high physical activity level, such as after amputation due to trauma or cancer, is currently limited by dependence on an external socket for the mechanical attachment of the prosthesis to the residuum. Despite the use of advanced materials and fabrication methods, socket interfaces routinely cause sores, chafing, pain, increased energy expenditure, and a decreased quality of life. Novel surgical techniques using osseointegrated transdermal titanium implants, now validated in Europe for 25 years, obviate the need for painful sockets by establishing a direct, load-bearing link between skeleton and prosthesis. This system also promises a transformative breakthrough in neuroprosthetics, because it allows for fully internal, high bandwidth, stable neural connections. In a paper recently published in Science Translational Medicine, implanted muscle and nerve cuff electrodes were added to the osseointegrated device, creating a bi-directional efferent-afferent interface utilizing a safe and immune-sealed osseo-conduit. Commenting on this work, the editor stated, "Osseointegration could revolutionize the field of neuroprosthetics, giving patients more intuitive control and more freedom of movement."

Investigators have sought to advance bionic prostheses with sufficient degrees of freedom for performing natural tasks, such as manipulating objects in the case of upper-extremity prostheses, or walking and running for lower-extremity systems. Nonetheless, afferent feedback has not played a major role in any clinically-viable amputation prostheses, despite being critical for biomimetic control. This deficiency can, in large part, be attributed to a lack of clinically-available methodologies for sustained communication with the peripheral nervous system. There is no existing platform capable of invasive, robust, and permanent communication with the peripheral nervous system in a high-demand clinical setting. Only by bringing together critical technologies and expertise will it be possible to create a bionic limb replacement system with adequate suspension, load transmission, motor control, proprioceptive feedback, and external mechatronics that resemble the mass, volume and dynamics of the missing biological limb.

To achieve such an unprecedented integration of prosthetic technology, a broad scientific team has been assembled with members from Massachusetts Institute of Technology (MIT: Carty, Herr, Riso, Braanemark), Brigham and Women's Hospital (BWH: Carty), University of California, San Francisco (UCSF: O'Donnell), University of Michigan (U-M: Cederna), and Walter Reed National Military Medical Center (WRNMMC: Forsberg, Potter). With this combination of leading technologists and clinicians in the fields of biomechanics, osseointegration, prosthetics, implantable electrodes, sensory feedback, proprioception, reconstructive surgery, and mechatronics, we seek to develop the most advanced clinically-viable artificial limb. With proprioceptive afferent feedback, we seek to demonstrate that a person with transtibial amputation can exhibit full volitional control over a neuro-mechanical prosthetic system where key walking metrics are normalized, including preferred speed, metabolism and joint dynamics. It is the view of the proposers that the scope of this research is fundamental wherein the results will be shared broadly within the scientific community.

Conditions
Amputation
Being tested
e-OPRA Implant System for Transtibial Amputees
Keywords
Osseointegration, Prosthesis, Neural Transmission

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • e-OPRA Implant System for Transtibial AmputeesDevice

    Also called e-OPRA

    The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.

Study groups in NCT05249049
Study groupRoleWhat they receive
e-OPRA Implant System for Transtibial AmputeesExperimentalImplantation of e-OPRA Implant System in lower limb.
Receives: Device: e-OPRA Implant System for Transtibial Amputees

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Electrode Robustness and Connector/Lead Integrity (resistance)

    Measured Impedance of electrode(kOhms)

    Measured: 24 months

  2. Electrode Robustness and Connector/Lead Integrity (amplitude)

    Maximal Voluntary Contraction Amplitude (mV)

    Measured: 24 months

  3. Sensor Function and Signal Quality

    Signal-to-noise ratio (SNR) above 2

    Measured: 24 months

Secondary outcomes (1)
  1. Preferred Walking Speed

    Preferred walking speed, as each subject ambulates with the neuromechanical prosthesis, will be evaluated. Preferred walking speed will be compared to a non-amputee height/weight match for each enrolled subject. A baseline data set will first be collected for each subject ambulating with a conventional prosthesis. Each subject will be timed as they traverse a predetermined distance at a steady speed that they deem most comfortable.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2022
  2. Study start3 Nov 2021
  3. Primary completion31 Dec 2022 (estimated)
  4. Study completion15 Apr 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
2 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05249049
Sponsor's protocol ID
2012000283
Acronym
TTeOPRA
Status last verified
Feb 2022
First submitted
3 Dec 2021
Last updated
21 Feb 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A study testing e-OPRA Implant System for Transtibial Amputees in people with Amputation, run by Massachusetts Institute of Technology at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hugh M Herr, PhD (617-314-3661, hherr@media.mit.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Electrode Robustness and Connector/Lead Integrity (resistance) (time frame: 24 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in